Targeting the purinergic system for disease-modification in epilepsy

Project description

Novel therapeutic targets in epilepsy

Epilepsy is a neurological condition that is characterised by seizures. Current therapies are ineffective in nearly 30 % of patients, necessitating the development of novel treatments. The EU-funded EpiPurines project is focusing on the purinergic signalling system, which is activated by nucleotides and nucleosides. Using disease animal models and induced pluripotent stem cells, scientists will investigate the outcome of targeting various receptors and enzymes implicated in the system's pathways. Results will help us understand the role of purinergic signalling in epileptogenesis and pave the way for new drugs that offer improved seizure control and suppression of epilepsy.

Fields of science

• medical and health sciences › basic medicine › neurology › epilepsy

Programme(s)

• H2020-EU.1.3. - EXCELLENT SCIENCE - Marie Skłodowska-Curie Actions Main Programme
• H2020-EU.1.3.2. - Nurturing excellence by means of cross-border and cross-sector mobility

Topic(s)

• MSCA-IF-2020 - Individual Fellowships

Call for proposal

H2020-MSCA-IF-2020

See other projects for this call

Funding Scheme

MSCA-IF-GF - Global Fellowships

Coordinator

ROYAL COLLEGE OF SURGEONS IN IRELAND

Net EU contribution

€ 257 561,28

Address

Saint Stephen's Green 123
2 Dublin
Ireland

Activity type

Higher or Secondary Education Establishments

Non-EU contribution

€ 0,00

Region

Ireland › Northern and Western › Border

Partners (1)

Partner

Partner organisations contribute to the implementation of the action, but do not sign the Grant Agreement.

RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY

United States

Net EU contribution

€ 0,00

Address

Rutgers Plaza 3
08901 New Brunswick

Activity type

Higher or Secondary Education Establishments

Non-EU contribution

€ 165 265,92